Table 2.
Multivariate analysis of prognostic factors for overall survival (OS) and progression-free survival (PFS) in patients with intermediate-stage recurrent hepatocellular carcinoma (RHCC) after propensity score matching (PSM).
| Variable Comparison | Overall survival |
Progression-free survival |
|||
|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | ||
| Recurrent stage data | |||||
| Tumour diameter. cm | ≤3 vs. >3 | 1.54 (1.12–2.11) | 0.007 | 1.89 (1.46–2.44) | <0.001 |
| Tumour number | ≤3 vs. >3 | 2.57 (1.81–3.63) | <0.001 | 2.80 (2.21–3.69) | <0.001 |
| Recurrent stage | Late vs. Early | 1.81 (1.28–2.56) | 0.001 | 1.66 (1.27–2.16) | <0.001 |
| Types of treatment | TACE-sorafenib + RFA vs. TACE-sorafenib | 2.41 (1.77–3.26) | <0.001 | 2.71 (2.10–3.50) | <0.001 |
| Initial hepatectomy stage data | |||||
| Tumour diameter, cm | ≤5 | Reference | |||
| >5, <10 | 1.68 (0.89–2.58) | 0.074 | |||
| BCLC stage | ≥10 | 1.92 (1.18–3.12) | 0.009 | ||
| BCLC stage | A vs. B | 1.45 (1.05–2.00) | 0.022 | 1.44 (1.11–1.86) | 0.006 |
| MVI | Negative vs. Positive | 1.54 (1.14–2.09) | 0.005 | 1.24 (0.94–1.63) | 0.127 |
HR, hazard ratio; CI, confidence interval; TACE, transarterial chemoembolization; RFA, radiofrequency ablation; BCLC, Barcelona Clinic Liver Cancer; MVI, microvascular invasion.